Stammdaten
Unternehmen
| Name | KalVista Pharmaceuticals, Inc. |
|---|---|
| Ticker | KALV |
| CIK | 0001348911 |
Branche
| SIC-Code | 2834 |
|---|---|
| Beschreibung | Pharmaceutical Preparations |
Wertpapier
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Titel | KalVista Pharmaceuticals, Inc. |
Status
| Zuletzt geprüft | 2026-03-20 22:36:30.60085 |
|---|
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-04-30 | 10-K | -183,444,000 | -3.69 | 250,770,000 | 95,391,000 | |
| 2024-04-30 | 10-K | 50,000,000 | ||||
| 2020-04-30 | 10-K | 12,690,000 |
Fondsaktivität (letzte 3 Quartale)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -6,693 | 16.08 | -107,632.81 | -165,4% | |
| 2026-02-23 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,354 | 15.57 | -83,344.65 | -128,1% | |
| 2026-02-23 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3,975 | 15.57 | -61,878.03 | -95,1% | |
| 2026-02-23 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4,347 | 15.57 | -67,668.88 | -104,0% | |
| 2026-02-23 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,034 | 15.57 | -156,197.27 | -240,0% | |
| 2026-02-23 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -1,767 | 15.57 | -27,506.54 | -42,3% | |
| 2026-02-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1,163 | 15.00 | -17,445.00 | -26,8% | |
| 2026-02-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -1,038 | 15.00 | -15,570.00 | -23,9% | |
| 2026-02-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -1,109 | 15.00 | -16,635.00 | -25,6% | |
| 2026-02-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,354 | 15.70 | -52,657.80 | -80,9% | |
| 2025-12-08 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7,294 | 16.51 | -120,423.94 | -185,1% | |
| 2025-11-24 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -5,296 | 13.45 | -71,236.50 | -109,5% | |
| 2025-11-24 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -10,940 | 13.45 | -147,153.94 | -226,1% | |
| 2025-11-24 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -4,331 | 13.45 | -58,256.28 | -89,5% | |
| 2025-11-24 | Piekos Brian | Officer, Chief Financial Officer | Open Market Sale | -4,471 | 13.45 | -60,139.42 | -92,4% | |
| 2025-11-24 | Sweeny Nicole | Officer, Chief Commercial Officer | Open Market Sale | -3,813 | 13.45 | -51,288.66 | -78,8% | |
| 2025-11-18 | Yea Christopher | Officer, CHIEF DEVELOPMENT OFFICER | Open Market Sale | -2,683 | 14.48 | -38,848.23 | -59,7% | |
| 2025-11-18 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -4,466 | 14.48 | -64,665.00 | -99,4% | |
| 2025-11-18 | Audhya Paul K. | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -3,075 | 14.48 | -44,524.46 | -68,4% | |
| 2025-11-12 | Palleiko Benjamin L | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -3,328 | 11.55 | -38,438.40 | -59,1% |
Top-Fondshalter (aktuelles Quartal)
Keine Fondsdaten für das aktuelle Quartal vorhanden.